These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33861731)

  • 21. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of the Serum CRP Level With the Efficacy of Metformin in the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis.
    Shi L; Tan GS; Zhang K
    J Clin Lab Anal; 2016 Jan; 30(1):13-22. PubMed ID: 25277876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
    Mishriky BM; Cummings DM; Powell JR; Sewell KA; Tanenberg RJ
    Diabetes Metab; 2019 Apr; 45(2):102-109. PubMed ID: 30243806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
    Mazidi M; Karimi E; Rezaie P; Ferns GA
    J Diabetes Complications; 2017 Jul; 31(7):1237-1242. PubMed ID: 28479155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E; Monami M
    Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
    Waldrop G; Zhong J; Peters M; Goud A; Chen YH; Davis SN; Mukherjee B; Rajagopalan S
    J Diabetes Complications; 2018 Jan; 32(1):113-122. PubMed ID: 29074120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
    Liu X; Men P; Wang B; Cai G; Zhao Z
    Lipids Health Dis; 2019 Jun; 18(1):144. PubMed ID: 31208420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
    Liu J; Li L; Deng K; Xu C; Busse JW; Vandvik PO; Li S; Guyatt GH; Sun X
    BMJ; 2017 Jun; 357():j2499. PubMed ID: 28596247
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials.
    Atkin SL; Katsiki N; Banach M; Mikhailidis DP; Pirro M; Sahebkar A
    J Diabetes Complications; 2017 Sep; 31(9):1458-1464. PubMed ID: 28647512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive protection of incretin-based therapies in patients with type 2 diabetes mellitus: A systematic review and meta-analysis based on clinical studies.
    Chai S; Liu F; Yu S; Yang Z; Sun F
    J Diabetes Investig; 2023 Jul; 14(7):864-873. PubMed ID: 37147888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incretin-based therapies for patients with type 1 diabetes: a meta-analysis.
    Liu L; Shao Z; Xia Y; Qin J; Xiao Y; Zhou Z; Mei Z
    Endocr Connect; 2019 Mar; 8(3):277-288. PubMed ID: 30694794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
    Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
    Gilbert MP; Pratley RE
    Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of resveratrol supplementation on C-reactive protein (CRP) in type 2 diabetic patients: Results from a systematic review and meta-analysis of randomized controlled trials.
    Hosseini H; Koushki M; Khodabandehloo H; Fathi M; Panahi G; Teimouri M; Majidi Z; Meshkani R
    Complement Ther Med; 2020 Mar; 49():102251. PubMed ID: 32147058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
    Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
    Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?
    Mora PF; Johnson EL
    Endocr Pract; 2017 Jan; 23(1):89-99. PubMed ID: 27819769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.
    Igweokpala S; Sule NO; Douros A; Yu OHY; Filion KB
    Diabetes Obes Metab; 2024 Feb; 26(2):721-731. PubMed ID: 38031234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Zhang F; Xu S; Tang L; Pan X; Tong N
    Front Endocrinol (Lausanne); 2020; 11():288. PubMed ID: 32582019
    [No Abstract]   [Full Text] [Related]  

  • 39. The impacts of exercise interventions on inflammaging markers in overweight/obesity patients with heart failure: A systematic review and meta-analysis of randomized controlled trials.
    Malandish A; Gulati M
    Int J Cardiol Heart Vasc; 2023 Aug; 47():101234. PubMed ID: 37416483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.